Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2484 participants.
Also called NCT02520921
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,484 participants
- Registry
-
NCT02520921 -
2015-000947-18
-
- Other papers using this trial's data
- Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT02520921. Randomized; no masking; primary purpose treatment. Start 2016-06-13 (actual); primary completion 2024-07-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome
- Acronym
- ANDAMAN
- Condition
- Diabetes Mellitus
- Condition
- Acute Coronary Syndrome
- Condition
- Coronary Artery Disease
- Condition
- Obesity
- Intervention (Drug)
- Novel strategy Aspirin
- Intervention (Drug)
- Conventional strategy Aspirin
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02520921- Content hash
3f5f0fe088de5304908714f1be481fc35e2722e810ad7cd12982e287706f03d4